Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Therapix reports positive topline results from Phase 2a obstructive sleep apnea trial
Therapix Biosciences (NASDAQ:TRPX) reported topline results from its Phase 2a clinical study of THX-110 for the treatment of obstructive sleep apnea (OSA). THX-110 is a combination of dronabinol, or synthetic THC, and...
Liminal BioSciences names Moira Daniels to head regulatory affairs, quality assurance
Liminal BioSciences (TSX:LMNL; OTCQX:LMNL) appointed Moira Daniels as the new head of regulatory affairs and quality assurance based at the company’s offices in Cambridge, UK. “Moira brings many years of global...
BTIG hikes Cerus to buy with $7 PT
BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...
HCW cuts Sunesis Pharma PT to 50 cents from $1.50
H.C. Wainwright lowered its price target for Sunesis Pharmaceuticals (NASDAQ:SNSS) to 50 cents from $1.50, citing a reduction in the probability of success for the vecabrutinib program to 7% from 8%. The stock closed at...
Kadmon KD025 meets primary endpoint at interim analysis of pivotal GvHD trial
Kadmon Holdings’ (NYSE:KDMN) KD025 met its primary endpoint at an interim analysis of its registrational chronic graft-versus-host disease (cGVHD) trial. cGvHD is a deadly complication of hematopoietic stem cell...
X4 Pharma’s mavorixafor gets FDA breakthrough therapy designation for WHIM syndrome
The FDA granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor breakthrough therapy designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and myelokathexis, or...
BriaCell to present clinical findings at San Antonio Breast Cancer Symposium
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) will highlight its lead product candidate, Bria-IMT, in two poster sessions during the 2019 San Antonio Breast Cancer Symposium. The Dec. 12 poster will summarize the data...
BTIG starts Stoke Therapeutics at buy; PT $46
BTIG launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and $46 price target. The stock closed at $29.79 on Nov. 11. Stoke is focused on technology developed largely by the academic inventors of...
Imagin Medical i/Blue imaging system on schedule for design verification
Imagin Medical (CSE:IME; OTCQB:IMEXF) is making progress towards design verification of its i/Blue Imaging System functional product. The company has purchased and received components from established suppliers to meet...
Just a few of the companies we’ve highlighted along the way
